All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · represents biopharmaceutical research companies

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 9

S 891
Bipartisan Health Care Act
S 527
Prescription Pricing for the People Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 1095
Stop STALLING Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 5

Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance; insulin price cap; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Budget/Appropriations

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.